SK bioscience

본문바로가기

KOR ENG

sitemap

PR

SK bioscience company news updates

Press releases

SK bioscience and the Bill & Melinda Gates Foundation Agreed to Strengthen Partnership

2022.05.17
SK bioscience and GSK’s Adjuvanted COVID-19 Vaccine Candidate Meets Coprimary Objectives in a Phase III Study; Biologics License Application Submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea

2022.04.29
SK bioscience Reports Positive Phase III Immunogenicity Results of Its Adjuvanted Covid-19 Vaccine Clinical Trial of COVID-19 Vaccine, AS03-adjuvanted

2022.04.25
SK bioscience Initiates Clinical Development of Antiviral Nasal Spray for Prevention of COVID-19

2022.04.13
SK bioscience Submits Post Approval Change Application of Protein-Based COVID-19 Vaccine for Adolescent Authorization to KMFDS

2022. 04. 07
SK bioscience Submits Rolling Review of Nuvaxovid for Adolescent Authorization to KMFDS

2022.03.23
SK bioscience Announces Commencement of Booster Trial of Adjuvanted COVID-19 Vaccine Candidate ‘GBP510(AS03)’ in South Korea

2022. 03. 22
SK bioscience Begins Shipment of First Authorized Protein-Based COVID-19 Vaccine

2022. 02. 09
SK bioscience Complete Recruitment for Phase III Clinical Trial of COVID-19 Vaccine

2022. 01. 18
SK bioscience Obtained Biologics License Application Approval of Novavax’ COVID-19 Vaccine in Korea

2022. 01. 12